Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study

Radiation Oncology

Research

Jie Zhu¹  Lei Wu¹  Gang Wan¹  Qifeng Wang¹  Yi Wang¹  Lin Peng²  Yongtao Han²  Xuefeng Leng²  Li Jiang³  Xue Chen³ 

[1] Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, 55 South Renmin Ave, Fourth Section, 610041, Chengdu, Sichuan, China;Department of Thoracic Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China;School of Medicine, University of Electronic Science and Technology of China, Chengdu, China;Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, 55 South Renmin Ave, Fourth Section, 610041, Chengdu, Sichuan, China;

关键词: Neoadjuvant chemoradiotherapy;    Esophageal squamous cell carcinoma;    Locally advanced esophageal squamous cell carcinoma;    Carboplatin;    Cisplatin;    Paclitaxel;    Adverse effects;    Overall survival;    Progression-free survival;   

DOI  :  10.1186/s13014-022-02190-4

 received in 2022-09-19, accepted in 2022-12-26,  发布年份 2022

来源: Springer

【 摘 要 】

Background and purposeWe evaluated and compared the efficacy and safety of chemotherapy with paclitaxel plus cisplatin (TP) or carboplatin (TC) in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC) who underwent neoadjuvant chemoradiotherapy (NCRT).Materials and methodsThis single-center retrospective study assessed patients with LA-ESCC (cT2N + M0, cT3-4aNanyM0) receiving NCRT plus curative-intent esophagectomy with TP or TC regimen. The primary endpoints were grade ≥ 3 adverse events (AEs) and overall survival (OS). AEs were compared using a t-test according to CTCAE 4.0. The Kaplan–Meier survival curves were compared using the log-rank test; the treatment effect was measured using hazard ratios and 95% confidence intervals.ResultsWe included 151 and 50 patients in the TC and TP groups, respectively. Baseline demographic and clinical characteristics were well balanced between groups. The TP group exhibited significantly higher hematologic and non-hematologic AEs than the TC group, and the noticeable difference was the incidence of febrile neutropenia of grade 3 or higher (P = 0.011). No significant intergroup differences were noted considering postoperative complications, resection margins, or pathological complete remission rate (all P > 0.05). OS and progression-free survival (PFS) did not significantly differ between groups. The estimated 3-year OS and PFS rates were 65.1% versus 69.4% and 58.4% versus 53.5% for TP and TC groups, respectively.ConclusionIn patients with LA-ESCC, we recommend TC, not TP, as an optimal chemotherapy regimen for NCRT, given its superiorsafety profile and comparable efficacy.

【 授权许可】

CC BY   
© The Author(s) 2022

【 图 表 】

12982_2022_119_Article_IEq70.gif

12982_2022_119_Article_IEq197.gif